Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors.
On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 34
- Registration Number
- NCT04403399
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Feasibility of Treatment for Vaping Cessation
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT04317300
A Novel Human Lab Model for Screening AUD Medications
- Conditions
- Alcohol Use Disorder
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 53
- Registration Number
- NCT04249882
- Locations
- 🇺🇸
UCLA Addictions Lab, Los Angeles, California, United States
Cannabis and Tobacco Co-use Study
- Conditions
- Tobacco Use Disorder
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 208
- Registration Number
- NCT04228965
- Locations
- 🇺🇸
Behavioral Health Services of Pickens County, Pickens, South Carolina, United States
🇺🇸Medical University of South Carolina - Charleston, Charleston, South Carolina, United States
🇺🇸Medical University of South Carolina - Florence, Florence, South Carolina, United States
Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction
- Conditions
- Smoking CessationHarm Reduction
- Interventions
- Drug: VareniclineOther: e-cigarette
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Rose Research Center, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT04210180
- Locations
- 🇺🇸
Rose Research Center, Raleigh, North Carolina, United States
Combining Varenicline and Guanfacine for Smoking Cessation
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Yale University
- Target Recruit Count
- 140
- Registration Number
- NCT04198116
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Health Systems Reach Interventions Project
- Conditions
- Smoking CessationSmoking, Cigarette
- Interventions
- Behavioral: Monetary incentives for initiating treatmentDrug: VareniclineDrug: Combination nicotine patch and nicotine mini-lozenge treatmentOther: Wisconsin Tobacco Quit Line referralBehavioral: Automated tailored outreachBehavioral: Care managementBehavioral: Untailored outreachOther: Primary care provider referralBehavioral: Multiple smoking cessation coaching calls
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 216
- Registration Number
- NCT04199117
- Locations
- 🇺🇸
UW Center for Tobacco Research and Intervention, Madison, Wisconsin, United States
Mobile Health Interventions for Medication Adherence Among PLWH
- Conditions
- HIV/AIDSSmokingSmoking CessationHIV
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Duke University
- Registration Number
- NCT04191278
Optimizing Tobacco Use Treatment for PLWHA
- Conditions
- HIV/AIDSNicotine Dependence
- Interventions
- Drug: VareniclineBehavioral: Standard treatmentDrug: Nicotine patchBehavioral: Standard treatment + Managed Problem Solving (MAPS) adherence intervention
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 340
- Registration Number
- NCT04176172
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH)
- Conditions
- SmokingHuman Immunodeficiency Virus
- Interventions
- Drug: BupropionDrug: VareniclineBehavioral: Cognitive Behavioral TherapyDrug: Nicotine Replacement TherapyBehavioral: Relapse Prevention Text Messaging
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 12
- Registration Number
- NCT04135937
- Locations
- 🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.